Evidence map›Paper›PMID 37264759›Full record

ArticleJournal of cellular and molecular medicine2023

miR-138-5p targets MCU to inhibit mitochondrial biogenesis and colorectal cancer growth.

Jianjun Zhu, Chunle Zhang, Zhengjie Wang, Lihong Shi, Li Li, Hao Wu, Ming Liu

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. The Role of miR-138 in Cardiovascular Diseases.BioMed research international · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jianjun ZhuDepartment of Medical Cellular Biology and Genetics, Shanxi Medical University, Taiyuan, China.ORCID 0000-0001-5338-7825
Chunle ZhangDepartment of Nephrology, Kidney Research Institute, West China Hospital of Sichuan University, Chengdu, China.ORCID 0000-0002-1431-6503
Zhengjie WangDepartment of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Lihong ShiDepartment of Human Anatomy, Shanxi Medical University, Taiyuan, China.
Li LiDepartment of Medical Cellular Biology and Genetics, Shanxi Medical University, Taiyuan, China.
Hao WuDepartment of Medical Cellular Biology and Genetics, Shanxi Medical University, Taiyuan, China.
Ming LiuDepartment of Medical Cellular Biology and Genetics, Shanxi Medical University, Taiyuan, China.
Shanxi Medical University · CNSichuan University · CNThe Affiliated Yongchuan Hospital of Chongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

miR-138-5p has been identified as a novel cancer-related miRNA molecule in a variety of malignancies. However, the functions and mechanisms underlying miR-138-5p in colorectal carcinoma (CRC) remains largely unknown. In the present study, we analysed the biological effects and clinical significance of miR-138-5p in CRC. miR-138-5p expression was analysed by quantitative real-time PCR in CRC tissues and cell lines. The effects of miR-138-5p on CRC cell growth was detected by cell proliferation, colony formation, cell cycle and cell apoptosis assays in vitro and in vivo. Our data showed that miR-138-5p was significantly downregulated in CRC. Downregulated miR-138-5p was related with poor prognosis in patients with CRC. miR-138-5p suppressed CRC growth but promoted cell death both in vitro and in vivo. Online predictions and integrated experiments identified that miR-138-5p targeted MCU, and downregulated miR-138-5p promoted mitochondrial biogenesis in CRC. In the light of the underlying mechanisms, our results indicated that downregulated miR-138-5p led to increased expression of MCU, which subsequently increased the production of ROS to promote CRC growth. Our results indicated that downregulated miR-138-5p strengthened mitochondrial biogenesis through targeting MCU, thus contributing to CRC cell growth, which may provide a potential therapeutic target for CRC.

Indexed as

Colorectal NeoplasmsMicroRNAsCell LineCell ProliferationHumansOrganelle BiogenesisMicroRNAsMIRN138 microRNA, humancolorectal carcinomaMCUmiR-138-5pROStumour growth

Identifiers

PMID37264759
PMCPMC10399525
OpenAlexW4379093301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.